IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE | News
SAN RAFAEL, Calif. and BARCELONA, Spain–(BUSINESS WIRE)–February 15, 2022–
IMIDomics, Inc., a privately held, global biotechnology company focused on the discovery and development of novel targets and drugs for the treatment of patients with immune-mediated inflammatory diseases (IMID), today announced that Evotec SE ( FSE: EVT; MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) has taken a stake in the company. Along with this investment, a representative of Evotec will join the IMIDomics Board of Directors. No financial details were disclosed.
IMIDs affect nearly 1 in 10 people, limiting quality of life and creating significant challenges to physical and mental well-being. The complexity of these diseases means that even getting a diagnosis can be a long-term struggle for patients, and then finding a treatment that works can be a frustrating and time-consuming trial and error process.
This new investment will further advance IMIDomics’ Precision Discovery™ engine, which enables in-depth understanding of how IMIDs work in patients through a combination of clinical and computational expertise with patient biospecimens from the IMID Biobank. Vall d’Hebron Hospital, exclusive access to secure, anonymized clinical data collected from over 17,000 IMID patients and control subjects across 150 health centers, and proprietary biomolecular signatures generated by IMIDomics from those same patients. Ultimately, the engine’s goal is to discover drugs that will materially impact the lives of IMID patients.
“Evotec and IMIDomics are fully aligned in their goal of leveraging data to discover and develop effective, precisely-acting drugs of the future,” said Dr. Werner Lanthaler, CEO of Evotec. “By joining IMIDomics as a minority shareholder, we are excited to further develop our EVOequity portfolio of very promising companies with complementary technologies and assets.
“The still unmet needs in this huge and ever-expanding category of diseases demand that we leverage patient data holistically to decipher the causes of disease and find treatments. Evotec’s dedication to using data in drug discovery is why they are so closely tied to IMIDomics – they share our core mission of applying intersectional data to discover the next generation of targeted drugs and solutions. ‘companion diagnostic tools needed to more accurately address complex IMID diseases and positively impact the experience and outcomes of people living with them,’ said Juan Harrison, CEO of IMIDomics.
IMIDomics was founded in Barcelona, Spain in 2015 by Dr. Sara Marsal, Head of the Department of Rheumatology at Vall d’Hebron University Hospital, and Dr. Richard M. Myers, President and Scientific Director of the Institute of HudsonAlpha biotechnology. Existing investors in IMIDomics include DNS Capital, Tao Capital, The Pritzker Organization and Bristol Myers Squibb.
To learn more about IMIDomics, please visit www.imidomics.com.
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220215005553/en/
CONTACT: IMIDomics press contact:
Sylvia Aranda at Real Chemistry
KEYWORD: EUROPE SPAIN UNITED STATES NORTH AMERICA CALIFORNIA
SECTOR KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: IMIDomics, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 02/15/2022 09:00/DISC: 02/15/2022 09:02
Copyright BusinessWire 2022.